For the last two months I've been part of the clinical trials of an Adderall derivative, without the amphetamine. So far my labs have shown that the administration increases the activity of the phosphoinositol cycle via an indirect release of dopamine and noradrenaline.
More importantly, the labs show the test drug ( NZT ) is a substrate analog at monoamine transporters, at all doses, it prevents the re-uptake of these neurotransmitters by competing with endogenous monoamines for uptake.
Here's a snapshot of my brain activity after administration:
At the higher doses I've been prescibed over the last 15 days it's been shown that, in my system, NZT triggers direct release of norepinephrine and dopamine via the cytoplasmic transmitter pool, that is, NZT causes norepinephrine and dopamine efflux via transporter proteins, functionally reversing transporter action, which triggers a cascading release of catecholamines. This inversion leads to the release of large amounts of these neurotransmitters from the cytoplasm of the presynaptic neuron into the synapse, causing increased stimulation of post-synaptic receptors.
Yesterday I got this weeks dose, which is supposed to be tailored specifically for my genetics, check out the package it came in:
They wanted my my opinion on some of the promo materials they're going to use in June when they officially launch the drug for public use. Evidently I'm in one of the last clinical study groups of many over the last 10 years and the drug is already FDA approved.
S U C K E R